The use of ecmo in hiv/aids with pneumocystis jirovecii pneumonia: A case report and review of the literature

Kelly Cawcutt, Alice Gallo De Moraes, Sarah J. Lee, John G. Park, Gregory J. Schears, Michael E. Nemergut

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

There are few reports of extracorporeal membrane oxygenation (ECMO) therapy for respiratory failure because of Pneumocystis jirovecii pneumonia (PJP) in patients with acquired immunodeficiency syndrome (AIDS). None of the cases reported involvement of immune reconstitution inflammatory syndrome (IRIS), a paradoxical clinical worsening after the initiation of antiretroviral therapy (ART) in ART-naïve patients because of an exaggerated systemic inflammation with cell count recovery. We present a patient with newly diagnosed AIDS and PJP pneumonia that progressed to acute respiratory distress syndrome (ARDS) secondary to probable IRIS for which veno-venous ECMO was initiated. He transitioned to conventional ventilator after 57 days of ECMO therapy. However, he did not survive to hospital discharge. Combined with four previously reported cases of ARDS in human immunodeficiency virus patients secondary to PJP treated with ECMO, three of the five patients survived to ECMO decannulation. Extracorporeal membrane oxygenation is considered an accepted modality for adult patients with respiratory and/or cardiac failure refractory to maximal medical therapy. As ECMO becomes increasingly utilized in clinical practice, there is ongoing controversy regarding the appropriate selection of patients. In the past, contraindications to ECMO included immunocompromised states and conditions with known poor prognosis. The cases herein suggest the indications and contraindications warrant further discussion and research.

Original languageEnglish (US)
Pages (from-to)606-608
Number of pages3
JournalASAIO Journal
Volume60
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pneumocystis carinii
Extracorporeal Membrane Oxygenation
Pneumocystis Pneumonia
Oxygenation
Membranes
Immune Reconstitution Inflammatory Syndrome
Adult Respiratory Distress Syndrome
Respiratory Insufficiency
Acquired Immunodeficiency Syndrome
Therapeutics
Mechanical Ventilators
Viruses
Refractory materials
Patient Selection
Pneumonia
Heart Failure
Cell Count
HIV
Inflammation
Recovery

Keywords

  • Acquired immunodeficiency syndrome
  • Case report
  • Critical care
  • Extracorporeal membrane oxygenation
  • Human immunodeficiency virus
  • Immune reconstitution inflammatory syndrome
  • Pneumocystis jirovecii pneumonia

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

The use of ecmo in hiv/aids with pneumocystis jirovecii pneumonia : A case report and review of the literature. / Cawcutt, Kelly; Gallo De Moraes, Alice; Lee, Sarah J.; Park, John G.; Schears, Gregory J.; Nemergut, Michael E.

In: ASAIO Journal, Vol. 60, No. 5, 01.01.2014, p. 606-608.

Research output: Contribution to journalArticle

Cawcutt, Kelly ; Gallo De Moraes, Alice ; Lee, Sarah J. ; Park, John G. ; Schears, Gregory J. ; Nemergut, Michael E. / The use of ecmo in hiv/aids with pneumocystis jirovecii pneumonia : A case report and review of the literature. In: ASAIO Journal. 2014 ; Vol. 60, No. 5. pp. 606-608.
@article{5362b5bdabd8432c82d1e4357c0b0051,
title = "The use of ecmo in hiv/aids with pneumocystis jirovecii pneumonia: A case report and review of the literature",
abstract = "There are few reports of extracorporeal membrane oxygenation (ECMO) therapy for respiratory failure because of Pneumocystis jirovecii pneumonia (PJP) in patients with acquired immunodeficiency syndrome (AIDS). None of the cases reported involvement of immune reconstitution inflammatory syndrome (IRIS), a paradoxical clinical worsening after the initiation of antiretroviral therapy (ART) in ART-na{\"i}ve patients because of an exaggerated systemic inflammation with cell count recovery. We present a patient with newly diagnosed AIDS and PJP pneumonia that progressed to acute respiratory distress syndrome (ARDS) secondary to probable IRIS for which veno-venous ECMO was initiated. He transitioned to conventional ventilator after 57 days of ECMO therapy. However, he did not survive to hospital discharge. Combined with four previously reported cases of ARDS in human immunodeficiency virus patients secondary to PJP treated with ECMO, three of the five patients survived to ECMO decannulation. Extracorporeal membrane oxygenation is considered an accepted modality for adult patients with respiratory and/or cardiac failure refractory to maximal medical therapy. As ECMO becomes increasingly utilized in clinical practice, there is ongoing controversy regarding the appropriate selection of patients. In the past, contraindications to ECMO included immunocompromised states and conditions with known poor prognosis. The cases herein suggest the indications and contraindications warrant further discussion and research.",
keywords = "Acquired immunodeficiency syndrome, Case report, Critical care, Extracorporeal membrane oxygenation, Human immunodeficiency virus, Immune reconstitution inflammatory syndrome, Pneumocystis jirovecii pneumonia",
author = "Kelly Cawcutt and {Gallo De Moraes}, Alice and Lee, {Sarah J.} and Park, {John G.} and Schears, {Gregory J.} and Nemergut, {Michael E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MAT.0000000000000112",
language = "English (US)",
volume = "60",
pages = "606--608",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The use of ecmo in hiv/aids with pneumocystis jirovecii pneumonia

T2 - A case report and review of the literature

AU - Cawcutt, Kelly

AU - Gallo De Moraes, Alice

AU - Lee, Sarah J.

AU - Park, John G.

AU - Schears, Gregory J.

AU - Nemergut, Michael E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - There are few reports of extracorporeal membrane oxygenation (ECMO) therapy for respiratory failure because of Pneumocystis jirovecii pneumonia (PJP) in patients with acquired immunodeficiency syndrome (AIDS). None of the cases reported involvement of immune reconstitution inflammatory syndrome (IRIS), a paradoxical clinical worsening after the initiation of antiretroviral therapy (ART) in ART-naïve patients because of an exaggerated systemic inflammation with cell count recovery. We present a patient with newly diagnosed AIDS and PJP pneumonia that progressed to acute respiratory distress syndrome (ARDS) secondary to probable IRIS for which veno-venous ECMO was initiated. He transitioned to conventional ventilator after 57 days of ECMO therapy. However, he did not survive to hospital discharge. Combined with four previously reported cases of ARDS in human immunodeficiency virus patients secondary to PJP treated with ECMO, three of the five patients survived to ECMO decannulation. Extracorporeal membrane oxygenation is considered an accepted modality for adult patients with respiratory and/or cardiac failure refractory to maximal medical therapy. As ECMO becomes increasingly utilized in clinical practice, there is ongoing controversy regarding the appropriate selection of patients. In the past, contraindications to ECMO included immunocompromised states and conditions with known poor prognosis. The cases herein suggest the indications and contraindications warrant further discussion and research.

AB - There are few reports of extracorporeal membrane oxygenation (ECMO) therapy for respiratory failure because of Pneumocystis jirovecii pneumonia (PJP) in patients with acquired immunodeficiency syndrome (AIDS). None of the cases reported involvement of immune reconstitution inflammatory syndrome (IRIS), a paradoxical clinical worsening after the initiation of antiretroviral therapy (ART) in ART-naïve patients because of an exaggerated systemic inflammation with cell count recovery. We present a patient with newly diagnosed AIDS and PJP pneumonia that progressed to acute respiratory distress syndrome (ARDS) secondary to probable IRIS for which veno-venous ECMO was initiated. He transitioned to conventional ventilator after 57 days of ECMO therapy. However, he did not survive to hospital discharge. Combined with four previously reported cases of ARDS in human immunodeficiency virus patients secondary to PJP treated with ECMO, three of the five patients survived to ECMO decannulation. Extracorporeal membrane oxygenation is considered an accepted modality for adult patients with respiratory and/or cardiac failure refractory to maximal medical therapy. As ECMO becomes increasingly utilized in clinical practice, there is ongoing controversy regarding the appropriate selection of patients. In the past, contraindications to ECMO included immunocompromised states and conditions with known poor prognosis. The cases herein suggest the indications and contraindications warrant further discussion and research.

KW - Acquired immunodeficiency syndrome

KW - Case report

KW - Critical care

KW - Extracorporeal membrane oxygenation

KW - Human immunodeficiency virus

KW - Immune reconstitution inflammatory syndrome

KW - Pneumocystis jirovecii pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84907018105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907018105&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000112

DO - 10.1097/MAT.0000000000000112

M3 - Article

C2 - 25166733

AN - SCOPUS:84907018105

VL - 60

SP - 606

EP - 608

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 5

ER -